At Merck, we are committed to registering our medicines and vaccines in a timely fashion in markets where they are needed.

A major goal is to reduce the historic time lapse in product introduction between developed and developing countries. One way we strive to reach that goal is through prequalification of medicines and vaccines by the World Health Organization (WHO). WHO prequalification is required by UN agencies that often distribute health care products throughout developing countries, and is necessary in the absence of reliable national medicines safety authorities to certify that products meet required quality, safety and efficacy standards. As such, prequalification is an important step toward fostering global access.

• In May 2009, GARDASIL^® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was the first cervical cancer vaccine awarded WHO prequalification
• In October 2008, Merck announced that it had received WHO prequalification for ROTATEQ^® (Rotavirus Vaccine, Live, Oral, Pentavalent)
• In December 2008, Merck received WHO prequalification for MMR-II^® (Measles, Mumps, Rubella Virus Vaccine Live)
• In December 2008, our treatments for HIV/AIDS [STOCRIN^® (efavirenz), CRIXIVAN^® (indinavir sulfate) and ATRIPLA^® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) received WHO prequalification
• We are committed to work with the World Health Organization (WHO) for the prequalification of ISENTRESS^® (raltegravir)

To increase the transparency of the company's products' registration status, we are disclosing registration information for ROTATEQ, GARDASIL and our four antiretrovirals (ARVs), and updating this information every six months. Click below for details:

• ROTATEQ
• GARDASIL
• ATRIPLA
• CRIXIVAN
• ISENTRESS
• STOCRIN

Learn more about our commitment to register our HIV/AIDS medicines.

Learn more about our commitment to register our women's health products.

Learn more about our commitment to register our vaccines.